Precision Medicine and the Price of Equity

Medicine has increasingly moved toward more personalized approaches that utilize individual patient characteristics to tailor therapeutic interventions and predict outcomes. While advancements in precision medicine have garnered significant attention, the ways that this budding subset of technology intersects with existing health disparities are often overlooked. Precision medicine holds tremendous potential to transform healthcare, but it risks widening existing disparities if not managed inclusively. We highlight three core issues that further marginalize underserved communities: high costs, limited accessibility of precision medicine, and insufficient diversity in research that produces these innovations. We also propose opportunities for state and federal policymakers to mitigate these issues. Without deliberate policy interventions, these innovations may remain accessible only to privileged demographics, excluding underserved communities from life-saving treatments. Key policy recommendations include restructuring reimbursement frameworks, reducing drug prices, fostering diversity in clinical trials, and building strong community partnerships. These measures are essential to transforming precision medicine from a selective advantage to a universally accessible health benefit.